# Akeso Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/akeso-biopharma

- Industry: Biotechnology
- Headquarters: Zhongshan, China
- Website: www.akesobio.com
- Total disclosed funding: $215M
- Latest round: Series D (Nov 1, 2019)
- Investors on record: 18

## About

Established in 2012 and based in Zhongshan, China, Akeso Biopharma, Inc. operates as a biopharmaceutical company that provides biopharmaceutical R&D, production and commercialization. The company has many partners, such as Merck Sharp & Dohme, Summit Therapeutics and Dongrui Pharmaceuticals, etc. It has production base located in Guangzhou and Zhongshan and many offices located in Beijing, Shanghai and Nantong, etc. In June 2018, it cooperated with GE to establish the first biologics production plant in South China using GE FlexFactory technology. In April 2020, the company was listed on the Hongkong stock exchange and its stock code is 9926. In August 2021, its product - Anicor® (PD-1 monoclonal antibody, pacamprinizumab injection) was approved for marketing.

The company develops ACE platform and bispecific antibody development technology (Tetrabody. Its product pipelines include AK129 (PD-1/LAG3), AK130 (TIGIT/TGFß)?AK131 (PD-1/CD73), AK132 (Claudin18.2/CD47) and AK117(CD47). Products include Ketanix® and Anicor®. It can apply in patients with oncology, autoimmune, inflammatory and metabolic diseases.

The company will plan to develop innovative drugs, promote clinical and establish production base.

## Funding rounds

- Series D, Nov 1, 2019, $150M — OrbiMed Advisors, BOCOM International Asset Management, Sino Biopharmaceutical Limited, Triwise Capital, Loyal Valley Capital, Shenzhen Capital Real Estate Fund, Apricot Capital, CCB Private Equity Investment Management, K.WAH Group, AIHC Capital, CDG International Company Limited, Lake Bleu Capital
- Series C, Oct 30, 2018 — Ally Bridge Group, Triwise Capital, Shenzhen Capital Real Estate Fund, CCB Private Equity Investment Management
- Series B, Aug 28, 2017, $45M — GTJA Investment Group, Triwise Capital, Shenzhen Capital Real Estate Fund, Qianhai Ark Capital
- Series A, Nov 19, 2015, $20M — CCB Principal Capital Management, Qianhai Xino, Phaeron Capital, Shenzhen Capital Real Estate Fund

## Investors

- CCB Principal Capital Management — Series A
- Qianhai Xino — Series A
- Phaeron Capital — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A, Series B, Series C, Series D
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series B
- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series B, Series C, Series D
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series B
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series C
- CCB Private Equity Investment Management (https://capitalatlas.ai/funds/ccb-private-equity-investment-management) — Series C, Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series D
- BOCOM International Asset Management (https://capitalatlas.ai/funds/bocom-international-asset-management) — Series D
- Sino Biopharmaceutical Limited — Series D
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series D
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series D
- K.WAH Group — Series D
- AIHC Capital — Series D
- CDG International Company Limited — Series D
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series D